Figure Technology Solutions Announces Date for First Quarter 2026 Results

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) — Figure Technology Solutions (Nasdaq: FIGR; OPEN: FGRS), the leading blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, today announced that it plans to report its First Quarter 2026 results on Monday, May 11, 2026, after market close.

The company will host a conference call to discuss the results, outlook, and related matters the following morning, Tuesday, May 12, 2026, at 8:30 a.m. Eastern Time.

A live webcast of the conference call and supporting materials will be available at http://investors.figure.com. For those unable to listen to the live broadcast, a replay will be available at the same website after the event.

About Figure

Figure Technology Solutions, Inc. (Nasdaq: FIGR; OPEN: FGRS) is a blockchain-native capital marketplace that seamlessly connects origination, funding, and secondary market activity. More than 300 partners use its loan origination system and capital marketplace. Collectively, Figure and its partners have originated over $24 billion of home equity to date, among other products, making Figure’s ecosystem the largest non-bank provider of HELOCs. The fastest growing components are Figure Connect, its consumer credit marketplace, and Democratized Prime, Figure’s on-chain lend-borrow marketplace. Figure’s ecosystem also includes DART (Digital Asset Registry Technology) for asset custody and lien perfection, and $YLDS, an SEC-registered yield-bearing stablecoin that operates as a tokenized money market fund.

Figure is the market leader in real world asset (RWA) tokenization. The company has received AAA ratings from S&P and Moody’s on multiple loan securitizations, the first of its kind for blockchain finance. For more information, visit https://figure.com or follow Figure on LinkedIn.

News & Information Disclosure

Investors should note we may use our website (https://www.figure.com/), our investor relations website (https://investors.figure.com/), and the social media accounts of Figure, Figure Markets and/or Mike Cagney, our Co-Founder and Executive Chairman, as a means of disclosing information and for complying with our disclosure obligations under Regulation FD. These include X (@figure @mcagney, @figuremarkets), LinkedIn (https://www.linkedin.com/company/figuretechnologies/, https://www.linkedin.com/in/mikecagney/), Instagram (@figuretechnologies), Facebook (https://www.facebook.com/Figure/), and YouTube (@figuretechnologies). The information we post through these channels may be deemed material. Investors should monitor these channels in addition to reviewing our press releases, SEC filings, and public conference calls.

Investor Contact:

[email protected]



Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in person at McCormick Place in Chicago, IL, and online, May 29 – June 2, 2026. With three abstracts selected for rapid oral presentations and three abstracts selected for poster presentations, these data highlight the global innovation and clinical value of Ascentage Pharma’s portfolio, inclusive of Olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China; Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor; and Alrizomadlin (APG-115), an MDM2-p53 inhibitor.

The ASCO Annual Meeting showcases cutting-edge research in clinical oncology and advanced cancer therapies and is the world’s most prominent scientific gathering in the oncology community.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, “This marks Ascentage Pharma’s ninth consecutive year presenting at the ASCO Annual Meeting. We are pleased to once again present our global innovation and R&D capabilities on this premier international stage. The selection of data from multiple studies this year, including three rapid oral presentations, further underscores the global scientific community’s recognition of the clinical value of our drug candidates. We look forward to sharing comprehensive data during the meeting and continuing to accelerate our global clinical development programs, with the goal of bringing more treatment options to patients as soon as possible.”

The clinical studies to be presented at this year’s ASCO Annual Meeting are as follows:


Rapid oral presentations


Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)

  • Abstract #: 6513
  • Format: Rapid oral presentation
  • Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
  • Date and Time: May 30, 2026, 1:15 – 2:45 p.m., Central Time (May 31, 2026, 2:15 – 3:45 a.m., Beijing Time)
  • First Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)

  • Abstract #: 6510
  • Format: Rapid oral presentation
  • Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
  • Date and Time: May 30, 2026, 1:15 – 2:45 p.m., Central Time (May 31, 2026, 2:15 – 3:45 a.m., Beijing Time)
  • First Author: Weiming Li, MD, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Alrizomadlin (APG-115) alone or in combination with lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)

  • Abstract #: 10012
  • Format: Rapid oral presentation
  • Session Title: Pediatric Oncology II
  • Date and Time: May 30, 2026, 8:00 – 9:30 a.m., Central Time (May 30, 2026, 9:00 -10:30 p.m., Beijing Time)
  • First Author: Yizhuo Zhang, MD, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China


Poster Presentations


Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors

  • Abstract #: 11539
  • Format: Poster presentation
  • Session Title: Sarcoma
  • Date and Time: June 1, 2026, 1:30 – 4:30 p.m., Central Time (June 2, 2026, 2:30 – 5:30 a.m., Beijing Time)
  • First Author: Haibo Qiu, MD, PhD, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress

  • Abstract #: TPS6608
  • Format: Poster presentation
  • Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
  • Date and Time: June 1, 2026, 9:00 a.m. – 12:00 p.m., Central Time (June 1, 2026, 10:00 p.m. -Tuesday June 2, 2026, 1:00 a.m., Beijing Time)
  • First Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress

  • Abstract #: TPS7101
  • Format: Poster presentation
  • Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  • Date and Time: June 1, 2026, 9:00 a.m. – 12:00 p.m., Central Time (June 1, 2026, 10:00 p.m. -Tuesday June 2, 2026, 1:00 a.m., Beijing Time)
  • First Author: Matthew Steven Davids, MD, Dana-Farber Cancer Institute

* Olverembatinib, Lisaftoclax and Alrizomadlin are currently under investigation and have not yet been approved by the FDA in the US.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first- and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared global registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risks Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited, where the Company’s ordinary shares are listed, it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:

Stella Yang
Ascentage Pharma
[email protected]
+1 (301) 792-6286

Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282

Media Relations:

Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012



WD to Participate in Upcoming Investor Conferences

WD to Participate in Upcoming Investor Conferences

SAN JOSE, Calif.–(BUSINESS WIRE)–
Western Digital Corporation (Nasdaq: WDC) today announced management participation in the following upcoming investor conferences:

Event: Barclays 18th Annual Americas Select Conference 2026

Date: Tuesday, May 5, 2026, at 6:15 a.m. PT / 9:15 a.m. ET

Event: J.P. Morgan 2026 Global Technology, Media and Communications Conference

Date: Monday, May 18, 2026, at 1:10 p.m. PT / 4:10 p.m. ET

Event: Bank of America Global Technology Conference 2026

Date: Tuesday, June 2, 2026, at 8:40 a.m. PT / 11:40 a.m. ET

Event: 2026 Evercore Global TMT Conference

Date: Wednesday, June 3, 2026, at 8:45 a.m. PT / 11:45 a.m. ET

The management presentations will be available as live webcasts, accessible through Western Digital’s Investor Relations website at investor.wdc.com. Archived replays will be accessible through the website shortly after the conclusion of the presentations.

About WD

WD, also known as Western Digital, builds the storage infrastructure that powers certainty in the AI-driven data economy. At the forefront of innovation, WD partners with the world’s leading hyperscalers, cloud service providers, and enterprises to enable reliable storage solutions that are proven and trusted at scale. Driven by a culture of innovation and execution, WD helps customers store, protect, and use the world’s data with confidence. Follow WD on LinkedIn and learn more at www.wd.com.

© 2026 Western Digital Corporation or its affiliates. All rights reserved. Western Digital, the Western Digital design, and the Western Digital logo are registered trademarks or trademarks of Western Digital Corporation or its affiliates in the US and/or other countries. All other marks are the property of their respective owners.

Ambrish Srivastava

408.717.9765

[email protected]

Western Digital Investor Relations

[email protected]

Western Digital Media Relations

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Semiconductor Hardware Consumer Electronics Other Technology Technology

MEDIA:

AI Demand Sparks Q1 Double-Digit Growth in Asia Pacific’s Technology Services Market, ISG Index™ Finds

AI Demand Sparks Q1 Double-Digit Growth in Asia Pacific’s Technology Services Market, ISG Index™ Finds

Combined market up 16%, driven by 18% increase in XaaS demand

Managed services rebounds, up 2%, to break 4-quarter losing streak

SYDNEY–(BUSINESS WIRE)–
Spending on technology services in Asia Pacific grew by double digits in the first quarter, powered by AI-driven demand for cloud infrastructure services, while managed services saw modest growth, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, found.

The Asia Pacific ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows ACV for the combined market—both managed services and as-a-service (XaaS)—rose 16 percent versus the prior year, to US $7.1 billion. It was only the third quarter of double-digit growth the region has produced in the last two years. Versus the fourth quarter of 2025, the market was up 15 percent.

XaaS spending climbed 18 percent, to a record US $6.3 billion, the segment’s fastest growth in two years. With interest in AI continuing to rise, demand for infrastructure-as-a-service (IaaS) advanced 19 percent, to a record US $5.6 billion, while software-as-a-service (SaaS) increased 15 percent, to a record US $675 million. Asia Pacific’s XaaS spending has grown at a slower pace than the Americas or EMEA, averaging 13.5 percent a quarter over the last 18 months.

Managed services ACV, meanwhile, rose 1.9 percent, to US $791 million, breaking a four-quarter losing streak during which time this segment averaged a 23 percent quarterly decline over the prior year. Against the fourth quarter of 2025, ACV was down 8 percent. Within this segment, IT outsourcing (ITO) slumped 32 percent, to US $409 million. Business process outsourcing (BPO) fell by 14 percent, to US $133 million, while engineering services rose to US $249 million, up from US $22 million in the prior year.

A total of 61 managed services contracts was awarded in the first quarter, up 7 percent year on year, but down 6 percent against the prior quarter. The number of smaller deals, those between US $5 million and US $9 million, rose 19 percent versus the prior year.

“Asia Pacific continues to be a cloud-first market, with digital transformation and AI fueling demand for infrastructure and software services,” said Michael Gale, partner and regional leader, ISG Asia Pacific. “Managed services rebounded this quarter but still has not returned to the $1 billion run-rate that we saw several times in 2024.”

Results by Industry, Geography

Several of the region’s smaller industries increased their managed services spending significantly in the first quarter, including transportation, healthcare and business services, which were all up more than 100 percent. Among the larger verticals, banking, financial services and insurance (BFSI) rose 4 percent while manufacturing was flat and telecommunications was down significantly, off 60 percent from the prior year.

By geography, the smaller managed services markets of Southeast Asia, China and Korea were each up by triple digits versus the prior year. However, the larger markets weighed on overall results, with India down 9 percent, Australia-New Zealand down 33 percent and Japan down 54 percent.

New ISG AI Index™ Launched

ISG last week announced the launch of its ISG AI Index™, a first-of-its-kind benchmark that measures how AI is impacting the global technology and business services sector. The initial findings were presented during the ISG Index call last Thursday. They show that infrastructure-as-a-service (IaaS) has seen the greatest impact from AI, up 160 percent. Software as-a-service (SaaS) has risen 53 percent while managed services is up only slightly, at 0.3 percent. On a market-weighted basis, the composite ISG AI Index was up 77 percent since inception, dating to December 2022, just after the launch of ChatGPT 3.0 and the start of the current AI era. Visit this webpage for more details.

2026 Global Forecast

ISG said it is raising its full-year forecast for XaaS revenue growth to 25 percent, up 400 basis points from its January forecast, and is holding its managed services growth forecast at 2.1 percent for the year. The forecasts reflect ISG’s view that XaaS growth will continue to accelerate on strong demand for AI, while managed services growth will remain “steady” as enterprises focus on cost takeout to fund their AI initiatives.

About the ISG Index™

The ISG Index™ is recognized as the authoritative source for marketplace intelligence on the global technology and business services industry. For 94 consecutive quarters, it has detailed the latest industry data and trends for financial analysts, enterprise buyers, software and service providers, law firms, universities and the media.

The 1Q26 Global ISG Index results were presented during a webcast last week. To view a replay of the webcast and download presentation slides, visit this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Press Contacts:

Will Thoretz, ISG

+1 203 517 3119

[email protected]

Eric Arvidson, Matter Communications for ISG

+1 978-518-4542

[email protected]

KEYWORDS: Australia/Oceania Australia Asia Pacific

INDUSTRY KEYWORDS: Software Networks Professional Services Business Electronic Design Automation Data Management Apps/Applications Technology Artificial Intelligence Outsourcing Business Security Consulting

MEDIA:

Logo
Logo

Mid Penn Bancorp, Inc. Reports First Quarter Earnings and Declares 62nd Consecutive Quarterly Dividend

Mid Penn Bancorp, Inc. Reports First Quarter Earnings and Declares 62nd Consecutive Quarterly Dividend

HARRISBURG, Pa.–(BUSINESS WIRE)–
Mid Penn Bancorp, Inc. (NASDAQ: MPB) (“Mid Penn”), the parent company of Mid Penn Bank (the “Bank”) and MPB Financial Services, LLC, today reported net income available to common shareholders (“earnings”) of $8.7 million, or $0.36 per basic and diluted common share, for the quarter ended March 31, 2026, compared to $13.7 million, or $0.71 per basic and diluted common share, for the first quarter of 2025. Adjusted earnings per common share, excluding non-recurring income and expenses(1), was $0.64 for the first quarter of 2026. Adjustments exclude $7.7 million of merger-related expenses and $370 thousand of non-recurring compensation expenses, net of tax.

Key Highlights of the First Quarter of 2026:

  • On February 27, 2026, Mid Penn completed the acquisition of 1st Colonial Bancorp, Inc. (“1st Colonial”), which added total assets of $842.5 million, comprised primarily of $597.5 million of loans. Additionally, on January 1, 2026, Mid Penn completed the acquisition of Cumberland Advisors, Inc. (“Cumberland Advisors”), a registered investment advisory firm, with approximately $3.2 billion in assets under management, further expanding the Company’s wealth management capabilities and fee-based revenue.

  • Primarily driven by merger-related expenses associated with the 1st Colonial and Cumberland Advisors acquisitions, net income available to common shareholders was $8.7 million for the first quarter of 2026 compared to net income of $13.7 million for the first quarter of 2025. Earnings per basic and diluted common share for the first quarter of 2026 was $0.36, a decrease from $0.71 per both basic and diluted common share in the first quarter of 2025.

  • On a non-GAAP basis, adjusted net income excluding non-recurring income and expenses(1) for the quarter ended March 31, 2026, increased 10.0% to $15.3 million, compared to $13.9 million, for the first quarter of 2025, while adjusted earnings per common share was $0.64 compared to $0.72, reflecting a higher weighted-average share count following the Company’s recent acquisitions.

  • Net interest margin increased to 3.80% for the quarter ended March 31, 2026, compared to 3.79% for the fourth quarter of 2025, and 3.37% for the first quarter of 2025. This represents a 1 and 43 basis point (“bp”) increase compared to the fourth quarter of 2025 and first quarter of 2025, respectively. The increase, compared to the first quarter of 2025, was driven by higher loan and investment securities yields and a reduction in the cost of funds.

  • Loan balances increased $647.1 million, or 54.0% (annualized), during the first quarter of 2026. Excluding $597.5 million of loans acquired in the 1st Colonial transaction, organic loan growth was $49.6 million, or 4.1% (annualized), from December 31, 2025. Total loans increased $1.0 billion, or 22.7%, to $5.5 billion at March 31, 2026, compared to $4.5 billion at March 31, 2025.

  • Deposits increased $756.3 million, or 58.8% (annualized), during the first quarter of 2026, compared to a decrease of $128.1 million, or 9.5% (annualized), during the fourth quarter of 2025. Excluding $747.1 million of deposits acquired in the 1st Colonial transaction, organic deposits increased $9.3 million, or 0.7% (annualized), from December 31, 2025. Total deposits increased $1.2 billion, or 26.2%, to $6.0 billion at March 31, 2026, compared to $4.7 billion at March 31, 2025.

  • The core efficiency ratio(1) was 63.52% in the first quarter of 2026, compared to 55.26% in the fourth quarter of 2025, and 62.79% in the first quarter of 2025. The increase reflects the near-term impact of integrating the 1st Colonial and Cumberland Advisors acquisitions, including incremental operating costs, with anticipated cost synergies to be realized over future periods.

  • Book value per common share was $35.08 as of March 31, 2026, compared to $35.32 as of December 31, 2025, and $34.50 as of March 31, 2025. The modest decline from the prior quarter reflects the accounting impact of the 1st Colonial acquisition, including merger-related expenses and the issuance of common shares. Tangible book value per common share (1) was $27.56 as of March 31, 2026, compared to $28.76 and $27.58 as of December 31, 2025 and March 31, 2025, respectively, with the decline primarily reflecting the goodwill and other intangible assets recorded in connection with the 1st Colonial and Cumberland Advisors acquisitions, as well as the William Penn acquisition in 2025.

  • As a result of the foregoing, the Board of Directors declared a cash dividend of $0.22 per common share, payable on May 15, 2026, to shareholders of record as of May 4, 2026.

(1) Non-GAAP financial measure. Refer to the calculation in the section titled “Reconciliation of Non-GAAP Measures (Unaudited)” at the end of this document.

Chair, President and CEO Rory G. Ritrievi provided the following statement:

“As a result of the one-time M&A costs related to the finalization of the Cumberland Advisors and the 1st Colonial acquisitions, as well as other significant one-time expenses unrelated to M&A as discussed further within this release, the quarter was unusually noisy relative to analyst expectations.

However, with first quarter total revenues of $64.9 million and pre-provision net revenues of $12.9 million, we beat consensus estimates on both fronts. From a GAAP standpoint, our reported net income of $8.7 million also beat analyst consensus estimates.

Given the level of activity this quarter—including nearly $2 million of additional one-time, non-merger expenses —we are encouraged by our company’s revenue performance. Our relationship-focused calling team continues to drive net interest margin expansion in an increasingly competitive environment, and we are cautiously optimistic about both loan and deposit pipelines in the face of ongoing macroeconomic uncertainty. Further, noninterest income growth is strong, driven in no small part by the recent addition of Cumberland Advisors. Additionally, our experienced integration teams remain keenly focused on unlocking efficiencies in our recent merger activity, as projected over the coming quarters.

To reward our shareholders, we are happy to declare a quarterly cash dividend of $0.22 per common share, payable May 15, 2026, to shareholders of record as of May 4, 2026. We are also pleased to announce the reauthorization and expansion of our treasury stock repurchase program, which now accommodates up to an additional $50 million in repurchase activity.”

Net Interest Income

For the three months ended March 31, 2026, net interest income was $55.3 million, compared to net interest income of $54.8 million for the three months ended December 31, 2025. Interest income for the quarter ended March 31, 2026, includes $2.4 million of loan accretion income related to fair value marks on acquired loans, which are accreted into interest income over the expected life of the assets. The tax-equivalent net interest margin(1) for the three months ended March 31, 2026 was 3.80% compared to 3.79% and 3.37% for the fourth quarter of 2025 and first quarter of 2025, respectively, representing a 1 bp increase from the fourth quarter of 2025, and a 43 bp increase compared to the same period in 2025.

The yield on interest-earning assets decreased to 5.75% for the quarter ended March 31, 2026, from 5.86% for the three months ended December 31, 2025, and increased from 5.65% for the three months ended March 31, 2025. The decrease from the fourth quarter of 2025 was primarily due to a higher average balance of lower-yielding Fed funds sold.

For the three months ended March 31, 2026, net interest income increased 30.0% to $55.3 million compared to net interest income of $42.5 million for the same period of 2025. The increase was primarily driven by a $10.3 million increase in interest income on loans, and a $2.0 million increase in interest income on investment securities, compared to the same period in 2025.

Average Balances

Average balances were impacted by the 1st Colonial acquisition which closed on February 27, 2026. Day one increases in loans, total assets, deposits, and total liabilities were approximately $581.8 million, $842.5 million, $746.9 million, and $751.7 million, respectively.

Average loans increased $238.9 million to $5.1 billion for the quarter ended March 31, 2026, compared to $4.8 billion for the quarter ended December 31, 2025, and increased $623.6 million compared to $4.5 billion for the quarter ended March 31, 2025.

Average deposits were $5.4 billion for the first quarter of 2026, reflecting an increase of $103.0 million, or 1.9%, compared to total average deposits of $5.3 billion in the fourth quarter of 2025, and an increase of $711.9 million, or 15.2%, compared to total average deposits of $4.7 billion for the first quarter of 2025, primarily due to the 1st Colonial and William Penn acquisitions and organic growth. The average cost of deposits was 2.09% for the first quarter of 2026, representing a 20 bp decrease from the fourth quarter of 2025, and a 35 bp decrease from the first quarter of 2025, respectively.

Cost of funds decreased to 2.12%, compared to 2.26% in the fourth quarter of 2025, primarily reflecting the repricing of higher-cost time deposits and money market accounts, as well as a favorable shift in the funding mix, including increased noninterest-bearing deposits added through the 1st Colonial acquisition.

Asset Quality

The total provision for credit losses, including benefit for credit losses on off-balance sheet credit exposures, was $1.6 million for the three months ended March 31, 2026, compared to the benefit for credit losses of $839 thousand for the three months ended December 31, 2025, and a provision for credit losses of $301 thousand for the three months ended March 31, 2025. The quarter-over-quarter change in the provision for credit losses was primarily driven by qualitative adjustments to the CRE owner-occupied portfolio, reflecting growth within that segment, offset by decreases due to higher prepayment speeds and a favorable economic forecast. Net charge offs for the three months ended March 31, 2026 were $1.0 million, or approximately 0.02% of total average loans.

The provision for credit losses on loans was $1.6 million for the three months ended March 31, 2026, an increase of $1.3 million compared to the provision for credit losses of $321 thousand for the three months ended March 31, 2025. The increase for the three months ended March 31, 2026 was primarily attributable to qualitative adjustments to several segments of the portfolio, offset by decreases due to a favorable economic forecast. The benefit for credit losses on off-balance sheet credit exposures was $54 thousand for the three months ended March 31, 2026, compared to $20 thousand for the three months ended March 31, 2025.

Allowance for credit losses – loans was 0.75%, 0.74%, and 0.80% of loans, net of unearned income at March 31, 2026, December 31, 2025, and March 31, 2025, respectively.

Total nonperforming assets were $38.1 million at March 31, 2026, compared to nonperforming assets of $30.8 million at December 31, 2025 and $25.4 million at March 31, 2025. The increase during the first quarter of 2026 was primarily driven by the addition of $7.4 million of nonaccrual loans from the 1st Colonial acquisition. Delinquency, measured as loans past due 30 days or more, as a percentage of total loans was 0.70% at March 31, 2026, compared to 0.69% and 0.50% as of December 31, 2025 and March 31, 2025, respectively.

Capital

Shareholders’ equity increased $73.3 million, or 9.0%, to $887.4 million as of March 31, 2026, from $814.1 million as of December 31, 2025. Retained earnings increased $2.5 million, or 1.1%, to $222.2 million as of March 31, 2026. Regulatory capital ratios for both Mid Penn and the Bank indicate regulatory capital levels in excess of both the regulatory minimums and the levels necessary for the Bank to be considered “well capitalized” at March 31, 2026. Additionally, Mid Penn declared $6.2 million in dividends during the first quarter of 2026.

On April 21, 2026, Mid Penn’s Board of Directors authorized an increase to its treasury stock repurchase program (“the Program”), increasing the amount available to repurchase to $50.0 million of Mid Penn’s outstanding common stock through April 30, 2027. No shares were purchased during the three months ended March 31, 2026. As of March 31, 2026, Mid Penn repurchased a total of 519,891 shares of common stock at an average price of $23.65 per share under the Program.

Noninterest Income

For the three months ended March 31, 2026, noninterest income totaled $9.6 million, an increase of $2.3 million, or 32.0%, from $7.3 million for the fourth quarter of 2025. The increase was primarily driven by a $2.2 million increase in fiduciary and wealth management income from the Cumberland Advisors acquisition.

For the three months ended March 31, 2026, noninterest income totaled $9.6 million, an increase of $4.4 million, or 83.3%, compared to noninterest income of $5.2 million for the three months ended March 31, 2025. The increase is primarily driven by a $2.5 million increase in fiduciary and wealth management income, a $431 thousand increase in earnings from the cash surrender value of life insurance, a $1.3 million increase in other noninterest income, including a $558 thousand increase in death benefits received, and a $458 thousand increase in insurance commissions.

Noninterest Expense

For the three months ended March 31, 2026, noninterest expense totaled $52.0 million, an increase of $16.1 million, or 44.9%, compared to $35.8 million in the fourth quarter of 2025. The increase was primarily driven by a $7.8 million increase in merger and acquisition expenses, a $3.3 million increase in salaries and employee benefits, a $696 thousand increase in legal and professional fees, and a $2.3 million increase in other noninterest expense, primarily driven by a $1.5 million increase related to a change in methodology for LIHTC amortization, and $665 thousand in legal settlements.

For the three months ended March 31, 2026, noninterest expense totaled $52.0 million, an increase of $21.3 million, or 69.6%, compared to $30.6 million for the three months ended March 31, 2025.

Merger and acquisition expenses increased $7.4 million to $7.7 million for the three months ended March 31, 2026, driven by $7.2 million related to the 1st Colonial acquisition, $544 thousand related to the Cumberland Advisors acquisition, compared to $314 thousand in the same period of 2025.

Salaries and benefits increased $7.0 million for the three months ended March 31, 2026, compared to the same period in 2025. The increase is attributable to (i) the retail staff additions at the twelve retail locations added through the William Penn acquisition and three retail locations added through the 1st Colonial acquisition; (ii) the retention of various William Penn and 1st Colonial team members through the completion of systems integrations; and (iii) the addition of staff members from the Cumberland Advisors acquisition.

Software licensing and utilization costs increased $1.0 million for the three months ended March 31, 2026, compared to the same period in 2025. The increase reflects additional costs to (i) license the additional William Penn and 1st Colonial branches; and (ii) upgrade internal systems, including network storage, cybersecurity, and data security enhancements in response to the Bank’s larger size and increased IT complexity.

Occupancy expenses increased $979 thousand for the three months ended March 31, 2026, compared to the same period in 2025. The increase was driven by the facility operating costs of the additional retail locations added through the William Penn, 1st Colonial, and Cumberland Advisors acquisitions.

The core efficiency ratio(1) was 63.5% for the first quarter of 2026, compared to 55.3% for the fourth quarter of 2025 and 62.8% for the first quarter of 2025. The change in the core efficiency ratio during the first quarter of 2026 compared to the fourth quarter of 2025 was primarily driven by higher core noninterest expenses associated with the addition of 1st Colonial, including incremental personnel and operating costs, which more than offset growth in net interest income. The Company continues to evaluate opportunities to achieve cost synergies as integration progresses.

1st Colonial Acquisition

On February 27, 2026, Mid Penn completed its acquisition of 1st Colonial through the merger of 1st Colonial with and into Mid Penn.

Each share of 1st Colonial common stock issued and outstanding as of February 27, 2026, was converted into the right to receive either 0.695 shares of Mid Penn common stock and cash in lieu of fractional shares or $18.50 per share of 1st Colonial common stock. Mid Penn issued approximately 2,111,076 shares of Mid Penn common stock and paid holders of 1st Colonial common stock approximately $37.5 million in cash. Mid Penn also recorded Goodwill of $15.3 million, and a core deposit intangible asset of $17.3 million as a result of this acquisition.

Cumberland Advisors Acquisition

On January 1, 2026, Mid Penn completed its acquisition of Cumberland Advisors, Inc., a registered investment advisory firm headquartered in Sarasota, Florida, with approximately $3.2 billion in assets under management.

Each share of Cumberland Advisors common stock issued and outstanding as of January 1, 2026 was converted into the right to receive 17.79 shares of Mid Penn common stock or $539.22 for each share of Cumberland Advisors common stock owned. As a result of the acquisition, Mid Penn paid holders of Cumberland Advisors common stock approximately $1.7 million in cash and issued approximately 127,009 shares of Mid Penn common stock. Mid Penn also recorded Goodwill of $5.1 million, customer list intangible assets of $2.1 million, and non-compete intangible assets of $219 thousand as a result of this acquisition.

(1) Non-GAAP financial measure. Refer to the calculation in the section titled “Reconciliation of Non-GAAP Measures (Unaudited)” at the end of this document. Non-GAAP financial measure.

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This press release, and oral statements made regarding the subjects of this release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not historical facts and include expressions about management’s confidence and strategies and management’s current views and expectations about new and existing programs and products, relationships, opportunities, technology, and market conditions. These statements may be identified by such forward-looking terminology as “continues,” “expect,” “look,” “believe,” “anticipate,” “may,” “will,” “should,” “projects,” “strategy” or similar statements. Actual results may differ materially from such forward-looking statements, and no reliance should be placed on any forward-looking statement. Factors that may cause results to differ materially from such forward-looking statements include, but are not limited to, changes in interest rates, spreads on earning assets and interest-bearing liabilities, and interest rate sensitivity; prepayment speeds, loan originations, credit losses and market values on loans, collateral securing loans, and other assets; sources of liquidity; common shares outstanding; common stock price volatility; fair value of and number of stock-based compensation awards to be issued in future periods; the impact of changes in market values on securities held in Mid Penn’s portfolio; legislation affecting the financial services industry as a whole, and Mid Penn and Mid Penn Bank individually or collectively, including tax legislation; results of the regulatory examination and supervision process and oversight, including changes in monetary policy and capital requirements; changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or regulatory agencies; increasing price and product/service competition by competitors, including new entrants; rapid technological developments and changes; the ability to continue to introduce competitive new products and services on a timely, cost-effective basis; the mix of products/services; containing costs and expenses; governmental and public policy changes; protection and validity of intellectual property rights; reliance on large customers; technological, implementation and cost/financial risks in large, multi-year contracts; the outcome of future litigation and governmental proceedings, including tax-related examinations and other matters; continued availability of financing; the availability of financial resources in the amounts, at the times and on the terms required to support Mid Penn and Mid Penn Bank’s future businesses; material differences in the actual financial results of merger, acquisition and investment activities compared with Mid Penn’s initial expectations, including the full realization of anticipated cost savings and revenue enhancements, the possibility that the anticipated benefits of a transaction are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in legacy Mid Penn and target markets; diversion of management’s attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of a transaction; the ability to complete the integration of Mid Penn and its target successfully; the dilution caused by Mid Penn’s issuance of additional shares of its capital stock in connection with a transaction; and other factors that may affect the future results of Mid Penn.

For a more detailed description of these and other factors which would affect our results, please see Mid Penn’s filings with the SEC, including those risk factors identified in the “Risk Factors” section and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings with the SEC. The statements in this press release are made as of the date of this press release, even if subsequently made available by Mid Penn on its website or otherwise. Mid Penn does not undertake, and specifically disclaims any obligation, to publicly release the result of any revisions which may be made to forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of unanticipated events, except as required by law.

SUMMARY FINANCIAL HIGHLIGHTS (Unaudited):

(Dollars in thousands, except per share data)

Mar. 31,

2026

 

Dec. 31,

2025

 

Sep. 30,

2025

 

Jun. 30,

2025

 

Mar. 31,

2025

Ending Balances:

 

 

 

 

 

 

 

 

 

Investment securities

$

830,499

 

 

$

769,045

 

 

$

781,888

 

 

$

769,211

 

 

$

634,044

 

Loans, net of unearned income

 

5,509,940

 

 

 

4,862,838

 

 

 

4,821,134

 

 

 

4,832,898

 

 

 

4,491,167

 

Total assets

 

6,964,809

 

 

 

6,133,896

 

 

 

6,267,349

 

 

 

6,354,543

 

 

 

5,546,026

 

Total deposits

 

5,970,967

 

 

 

5,214,663

 

 

 

5,342,720

 

 

 

5,449,664

 

 

 

4,732,202

 

Shareholders’ equity

 

887,405

 

 

 

814,058

 

 

 

796,323

 

 

 

775,708

 

 

 

667,933

 

Average Balances:

 

 

 

 

 

 

 

 

 

Investment securities

 

783,768

 

 

 

774,962

 

 

 

782,020

 

 

 

652,105

 

 

 

639,580

 

Loans, net of unearned income

 

5,083,240

 

 

 

4,844,308

 

 

 

4,804,163

 

 

 

4,724,638

 

 

 

4,459,679

 

Total assets

 

6,393,011

 

 

 

6,202,310

 

 

 

6,385,751

 

 

 

6,036,045

 

 

 

5,491,763

 

Total deposits

 

5,393,592

 

 

 

5,290,598

 

 

 

5,468,144

 

 

 

5,159,754

 

 

 

4,681,708

 

Shareholders’ equity

 

845,553

 

 

 

803,093

 

 

 

783,547

 

 

 

670,491

 

 

 

660,964

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

Income Statement:

Mar. 31,

2026

 

Dec. 31,

2025

 

Sep. 30,

2025

 

Jun. 30,

2025

 

Mar. 31,

2025

Net interest income

$

55,250

 

 

$

54,751

 

 

$

53,629

 

 

$

48,206

 

 

$

42,509

 

Provision/(benefit) for credit losses (4)

 

1,594

 

 

 

(839

)

 

 

(434

)

 

 

2,269

 

 

 

301

 

Noninterest income

 

9,604

 

 

 

7,277

 

 

 

8,183

 

 

 

6,143

 

 

 

5,239

 

Noninterest expense

 

51,959

 

 

 

35,848

 

 

 

37,982

 

 

 

47,798

 

 

 

30,642

 

Income before provision for income taxes

 

11,301

 

 

 

27,019

 

 

 

24,264

 

 

 

4,282

 

 

 

16,805

 

Provision/(benefit) for income taxes

 

2,595

 

 

 

7,572

 

 

 

5,967

 

 

 

(480

)

 

 

3,063

 

Net income available to shareholders

 

8,706

 

 

 

19,447

 

 

 

18,297

 

 

 

4,762

 

 

 

13,742

 

Net income excluding non-recurring income and expenses (1)

 

15,294

 

 

 

19,224

 

 

 

17,772

 

 

 

15,074

 

 

 

13,907

 

 

 

 

 

 

 

 

 

 

 

Per Share:

 

 

 

 

 

 

 

 

 

Basic earnings per common share

$

0.36

 

 

$

0.84

 

 

$

0.80

 

 

$

0.22

 

 

$

0.71

 

Diluted earnings per common share

 

0.36

 

 

 

0.83

 

 

 

0.79

 

 

 

0.22

 

 

 

0.71

 

Cash dividends declared

 

0.22

 

 

 

0.22

 

 

 

0.20

 

 

 

0.20

 

 

 

0.20

 

Book value per common share

 

35.08

 

 

 

35.32

 

 

 

34.56

 

 

 

33.85

 

 

 

34.50

 

Tangible book value per common share (1)

 

27.56

 

 

 

28.76

 

 

 

27.96

 

 

 

27.22

 

 

 

27.58

 

 

 

 

 

 

 

 

 

 

 

Asset Quality:

 

 

 

 

 

 

 

 

 

Net charge-offs/(recoveries) to average loans (3)

 

0.084

%

 

 

0.038

%

 

 

0.008

%

 

 

0.069

%

 

 

(0.0003

%)

Non-performing loans to total loans

 

0.54

 

 

 

0.47

 

 

 

0.37

 

 

 

0.38

 

 

 

0.54

 

Non-performing asset to total loans and other real estate

 

0.69

 

 

 

0.63

 

 

 

0.57

 

 

 

0.58

 

 

 

0.57

 

Non-performing asset to total assets

 

0.55

 

 

 

0.50

 

 

 

0.44

 

 

 

0.44

 

 

 

0.46

 

ACL on loans to total loans

 

0.75

 

 

 

0.74

 

 

 

0.77

 

 

 

0.78

 

 

 

0.80

 

ACL on loans to nonperforming loans

 

138.68

 

 

 

157.25

 

 

 

207.92

 

 

 

206.49

 

 

 

149.05

 

 

 

 

 

 

 

 

 

 

 

Profitability:

 

 

 

 

 

 

 

 

 

Return on average assets (3)

 

0.55

%

 

 

1.24

%

 

 

1.14

%

 

 

0.32

%

 

 

1.01

%

Return on average equity (3)

 

4.18

 

 

 

9.61

 

 

 

9.26

 

 

 

2.85

 

 

 

8.43

 

Return on average tangible common equity (1) (3)

 

5.82

 

 

 

12.29

 

 

 

11.95

 

 

 

4.05

 

 

 

10.84

 

Tax-equivalent net interest margin

 

3.80

 

 

 

3.79

 

 

 

3.60

 

 

 

3.44

 

 

 

3.37

 

Core Efficiency ratio (1)

 

63.52

 

 

 

55.26

 

 

 

58.80

 

 

 

62.56

 

 

 

62.79

 

 

 

 

 

 

 

 

 

 

 

Capital Ratios:

 

 

 

 

 

 

 

 

 

Tier 1 Capital (to Average Assets) (2)

 

11.4

%

 

 

11.0

%

 

 

10.4

%

 

 

10.6

%

 

 

10.2

%

Common Tier 1 Capital (to Risk Weighted Assets) (2)

 

12.7

 

 

 

13.5

 

 

 

13.9

 

 

 

12.8

 

 

 

12.0

 

Tier 1 Capital (to Risk Weighted Assets) (2)

 

12.7

 

 

 

13.5

 

 

 

13.9

 

 

 

12.8

 

 

 

12.0

 

Total Capital (to Risk Weighted Assets) (2)

 

13.5

 

 

 

14.3

 

 

 

15.5

 

 

 

14.4

 

 

 

13.8

 

(1)

Non-GAAP financial measure. Refer to the calculation in the section titled “Reconciliation of Non-GAAP Measures (Unaudited)” at the end of this document.

(2)

Regulatory capital ratios as of March 31, 2026 are preliminary estimates while prior period ratios are actual.

(3)

Annualized ratio

(4)

Includes $2.3 million related to non-PCD loans acquired in the William Penn acquisition on April 30, 2025. This amount reflects accounting guidance in effect prior to the Company’s adoption of ASU 2025-08, under which the allowance for certain purchased loans was recognized through provision expense.

CONSOLIDATED BALANCE SHEETS (Unaudited):

(Dollars in thousands, except share data)

Mar. 31,

2026

 

Dec. 31,

2025

 

Sep. 30,

2025

 

Jun. 30,

2025

 

Mar. 31,

2025

ASSETS

 

 

 

 

 

 

 

 

 

Cash and due from banks

$

60,967

 

 

$

46,695

 

 

$

18,013

 

 

$

52,671

 

 

$

47,688

 

Interest-bearing balances with other financial institutions

 

19,383

 

 

 

29,178

 

 

 

24,736

 

 

 

22,828

 

 

 

16,880

 

Federal funds sold

 

60,840

 

 

 

23,045

 

 

 

214,420

 

 

 

261,353

 

 

 

42,686

 

Total cash and cash equivalents

 

141,190

 

 

 

98,918

 

 

 

257,169

 

 

 

336,852

 

 

 

107,254

 

Investment Securities:

 

 

 

 

 

 

 

 

 

Held to maturity, at amortized cost

 

340,957

 

 

 

347,285

 

 

 

354,094

 

 

 

364,029

 

 

 

375,115

 

Available for sale, at fair value

 

484,130

 

 

 

416,314

 

 

 

427,352

 

 

 

404,745

 

 

 

258,493

 

Equity securities available for sale, at fair value

 

5,412

 

 

 

5,446

 

 

 

442

 

 

 

437

 

 

 

436

 

Loans held for sale

 

16,554

 

 

 

3,668

 

 

 

6,085

 

 

 

6,101

 

 

 

6,851

 

Loans, net of unearned income

 

5,509,940

 

 

 

4,862,838

 

 

 

4,821,134

 

 

 

4,832,898

 

 

 

4,491,167

 

Less: Allowance for credit losses

 

(41,105

)

 

 

(36,091

)

 

 

(37,337

)

 

 

(37,615

)

 

 

(35,838

)

Net loans

 

5,468,835

 

 

 

4,826,747

 

 

 

4,783,797

 

 

 

4,795,283

 

 

 

4,455,329

 

 

 

 

 

 

 

 

 

 

 

Premises and equipment, net

 

49,611

 

 

 

48,742

 

 

 

48,491

 

 

 

47,732

 

 

 

40,328

 

Operating lease right of use asset

 

16,803

 

 

 

15,169

 

 

 

15,700

 

 

 

15,026

 

 

 

9,402

 

Finance lease right of use asset

 

2,323

 

 

 

2,368

 

 

 

2,413

 

 

 

2,458

 

 

 

2,503

 

Cash surrender value of life insurance

 

116,474

 

 

 

95,351

 

 

 

95,015

 

 

 

94,770

 

 

 

51,351

 

Restricted investment in bank stocks

 

10,081

 

 

 

7,576

 

 

 

6,737

 

 

 

7,110

 

 

 

6,660

 

Accrued interest receivable

 

32,958

 

 

 

29,640

 

 

 

29,705

 

 

 

28,546

 

 

 

27,263

 

Deferred income taxes

 

23,798

 

 

 

21,416

 

 

 

27,475

 

 

 

35,333

 

 

 

21,800

 

Goodwill

 

157,121

 

 

 

136,620

 

 

 

136,620

 

 

 

135,473

 

 

 

128,160

 

Core deposit and other intangibles, net

 

33,013

 

 

 

14,657

 

 

 

15,586

 

 

 

16,531

 

 

 

5,814

 

Foreclosed assets held for sale

 

8,420

 

 

 

7,806

 

 

 

9,346

 

 

 

9,816

 

 

 

1,402

 

Other assets

 

57,129

 

 

 

56,173

 

 

 

51,322

 

 

 

54,301

 

 

 

47,865

 

Total Assets

$

6,964,809

 

 

$

6,133,896

 

 

$

6,267,349

 

 

$

6,354,543

 

 

$

5,546,026

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES & SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

Deposits:

 

 

 

 

 

 

 

 

 

Noninterest-bearing demand

$

933,497

 

 

$

834,013

 

 

$

836,374

 

 

$

857,072

 

 

$

788,316

 

Interest-bearing transaction accounts

 

3,357,497

 

 

 

2,829,175

 

 

 

2,852,361

 

 

 

2,770,877

 

 

 

2,368,837

 

Time

 

1,679,973

 

 

 

1,551,475

 

 

 

1,653,985

 

 

 

1,821,715

 

 

 

1,575,049

 

Total Deposits

 

5,970,967

 

 

 

5,214,663

 

 

 

5,342,720

 

 

 

5,449,664

 

 

 

4,732,202

 

 

 

 

 

 

 

 

 

 

 

Short-term borrowings

 

31,500

 

 

 

20,833

 

 

 

 

 

 

 

 

 

25,000

 

Long-term debt

 

3,021

 

 

 

23,139

 

 

 

23,258

 

 

 

23,374

 

 

 

23,489

 

Subordinated debt and trust preferred securities

 

 

 

 

 

 

 

37,149

 

 

 

37,303

 

 

 

45,587

 

Operating lease liability

 

17,186

 

 

 

15,405

 

 

 

15,973

 

 

 

15,342

 

 

 

9,765

 

Accrued interest payable

 

12,195

 

 

 

10,942

 

 

 

16,460

 

 

 

13,421

 

 

 

12,900

 

Other liabilities

 

42,535

 

 

 

34,856

 

 

 

35,466

 

 

 

39,731

 

 

 

29,150

 

Total Liabilities

 

6,077,404

 

 

 

5,319,838

 

 

 

5,471,026

 

 

 

5,578,835

 

 

 

4,878,093

 

 

 

 

 

 

 

 

 

 

 

Shareholders’ Equity:

 

 

 

 

 

 

 

 

 

Common stock, par value $1.00 per share; 40.0 million shares authorized

 

25,817

 

 

 

23,567

 

 

 

23,551

 

 

 

23,419

 

 

 

19,803

 

Additional paid-in capital

 

659,883

 

 

 

589,421

 

 

 

588,405

 

 

 

584,291

 

 

 

480,866

 

Retained earnings

 

222,154

 

 

 

219,685

 

 

 

205,320

 

 

 

191,574

 

 

 

191,469

 

Accumulated other comprehensive loss

 

(8,157

)

 

 

(6,323

)

 

 

(8,907

)

 

 

(11,756

)

 

 

(14,163

)

Treasury stock

 

(12,292

)

 

 

(12,292

)

 

 

(12,046

)

 

 

(11,820

)

 

 

(10,042

)

Total Shareholders’ Equity

 

887,405

 

 

 

814,058

 

 

 

796,323

 

 

 

775,708

 

 

 

667,933

 

Total Liabilities and Shareholders’ Equity

$

6,964,809

 

 

$

6,133,896

 

 

$

6,267,349

 

 

$

6,354,543

 

 

$

5,546,026

 

CONSOLIDATED STATEMENTS OF INCOME (Unaudited):

 

Three Months Ended

(Dollars in thousands, except per share data)

Mar. 31,

2026

 

Dec. 31,

2025

 

Sep. 30,

2025

 

Jun. 30,

2025

 

Mar. 31,

2025

INTEREST INCOME

 

 

 

 

 

 

 

 

 

Loans, including fees

$

76,798

 

$

76,916

 

 

$

76,262

 

 

$

72,469

 

 

$

66,537

 

Investment securities:

 

 

 

 

 

 

 

 

 

Taxable

 

6,501

 

 

6,590

 

 

 

6,614

 

 

 

4,637

 

 

 

4,460

 

Tax-exempt

 

297

 

 

320

 

 

 

331

 

 

 

344

 

 

 

348

 

Other interest-bearing balances

 

110

 

 

135

 

 

 

196

 

 

 

142

 

 

 

138

 

Federal funds sold

 

220

 

 

1,179

 

 

 

3,463

 

 

 

2,428

 

 

 

261

 

Total Interest Income

 

83,926

 

 

85,140

 

 

 

86,866

 

 

 

80,020

 

 

 

71,744

 

INTEREST EXPENSE

 

 

 

 

 

 

 

 

 

Deposits

 

27,848

 

 

29,930

 

 

 

32,631

 

 

 

30,981

 

 

 

28,264

 

Short-term borrowings

 

702

 

 

5

 

 

 

 

 

 

86

 

 

 

290

 

Long-term and subordinated debt

 

126

 

 

454

 

 

 

606

 

 

 

747

 

 

 

681

 

Total Interest Expense

 

28,676

 

 

30,389

 

 

 

33,237

 

 

 

31,814

 

 

 

29,235

 

Net Interest Income

 

55,250

 

 

54,751

 

 

 

53,629

 

 

 

48,206

 

 

 

42,509

 

Net (benefit)/provision for credit losses (1)

 

1,594

 

 

(839

)

 

 

(434

)

 

 

2,269

 

 

 

301

 

Net Interest Income After Provision for Credit Losses

 

53,656

 

 

55,590

 

 

 

54,063

 

 

 

45,937

 

 

 

42,208

 

NONINTEREST INCOME

 

 

 

 

 

 

 

 

 

Fiduciary and wealth management

 

3,661

 

 

1,412

 

 

 

1,340

 

 

 

1,406

 

 

 

1,140

 

ATM debit card interchange

 

1,035

 

 

1,053

 

 

 

1,019

 

 

 

958

 

 

 

919

 

Service charges on deposits

 

636

 

 

634

 

 

 

647

 

 

 

652

 

 

 

562

 

Mortgage banking

 

314

 

 

552

 

 

 

1,013

 

 

 

676

 

 

 

591

 

Mortgage hedging

 

81

 

 

(22

)

 

 

50

 

 

 

(7

)

 

 

(9

)

Net gain on sales of SBA loans

 

163

 

 

100

 

 

 

 

 

 

63

 

 

 

57

 

Earnings from cash surrender value of life insurance

 

705

 

 

609

 

 

 

605

 

 

 

491

 

 

 

274

 

Net gain on sales of investment securities

 

 

 

10

 

 

 

 

 

 

 

 

 

 

Other

 

3,009

 

 

2,929

 

 

 

3,509

 

 

 

1,904

 

 

 

1,705

 

Total Noninterest Income

 

9,604

 

 

7,277

 

 

 

8,183

 

 

 

6,143

 

 

 

5,239

 

NONINTEREST EXPENSE

 

 

 

 

 

 

 

 

 

Salaries and employee benefits

 

23,346

 

 

20,026

 

 

 

20,941

 

 

 

20,753

 

 

 

16,309

 

Software licensing and utilization

 

3,598

 

 

3,406

 

 

 

3,310

 

 

 

3,272

 

 

 

2,574

 

Occupancy, net

 

3,253

 

 

2,624

 

 

 

2,642

 

 

 

2,365

 

 

 

2,274

 

Equipment

 

1,553

 

 

1,435

 

 

 

1,248

 

 

 

1,248

 

 

 

1,094

 

Shares tax

 

964

 

 

245

 

 

 

1,006

 

 

 

606

 

 

 

919

 

Legal and professional fees

 

1,688

 

 

992

 

 

 

1,070

 

 

 

993

 

 

 

826

 

ATM/card processing

 

757

 

 

771

 

 

 

557

 

 

 

621

 

 

 

733

 

Intangible amortization

 

1,300

 

 

930

 

 

 

944

 

 

 

744

 

 

 

428

 

FDIC Assessment

 

800

 

 

1,046

 

 

 

422

 

 

 

994

 

 

 

990

 

Loss/(gain) on sale or write-down of foreclosed assets, net

 

491

 

 

203

 

 

 

471

 

 

 

 

 

 

(28

)

Merger and acquisition (2)

 

7,723

 

 

(39

)

 

 

233

 

 

 

11,011

 

 

 

314

 

Other

 

6,486

 

 

4,209

 

 

 

5,138

 

 

 

5,191

 

 

 

4,209

 

Total Noninterest Expense

 

51,959

 

 

35,848

 

 

 

37,982

 

 

 

47,798

 

 

 

30,642

 

INCOME BEFORE PROVISION FOR INCOME TAXES

 

11,301

 

 

27,019

 

 

 

24,264

 

 

 

4,282

 

 

 

16,805

 

Provision/(benefit) for income taxes

 

2,595

 

 

7,572

 

 

 

5,967

 

 

 

(480

)

 

 

3,063

 

NET INCOME AVAILABLE TO COMMON SHAREHOLDERS

$

8,706

 

$

19,447

 

 

$

18,297

 

 

$

4,762

 

 

$

13,742

 

 

 

 

 

 

 

 

 

 

 

PER COMMON SHARE DATA:

 

 

 

 

 

 

 

 

 

Basic Earnings Per Common Share

$

0.36

 

$

0.84

 

 

$

0.80

 

 

$

0.22

 

 

$

0.71

 

Diluted Earnings Per Common Share

 

0.36

 

 

0.83

 

 

 

0.79

 

 

 

0.22

 

 

 

0.71

 

Cash Dividends Declared

 

0.22

 

 

0.22

 

 

 

0.20

 

 

 

0.20

 

 

 

0.20

(1)

Includes $2.3 million related to non-PCD loans acquired in the William Penn acquisition on April 30, 2025. This amount reflects accounting guidance in effect prior to the Company’s adoption of ASU 2025-08, under which the allowance for certain purchased loans was recognized through provision expense.

(2)

Includes release of merger and acquisition accruals related to William Penn acquisition in the fourth quarter of 2025.

CONSOLIDATED – AVERAGE BALANCE SHEET AND NET INTEREST INCOME ANALYSIS (Unaudited):

 

Average Balances, Income and Interest Rates on a Taxable Equivalent Basis

 

For the Three Months Ended

 

March 31, 2026

 

December 31, 2025

 

March 31, 2025

(Dollars in thousands)

Average Balance

 

Interest

 

Yield/

Rate(2)

 

Average Balance

 

Interest

 

Yield/

Rate(2)

 

Average Balance

 

Interest

 

Yield/

Rate(2)

ASSETS:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Bearing Balances

$

19,647

 

$

110

 

2.27

%

 

$

21,590

 

$

135

 

2.48

%

 

$

20,794

 

$

138

 

2.69

%

Investment Securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Taxable

 

715,209

 

 

6,486

 

3.68

 

 

 

711,663

 

 

6,477

 

3.61

 

 

 

569,800

 

 

4,309

 

3.07

 

Tax-Exempt

 

68,559

 

 

297

 

1.76

 

 

 

63,299

 

 

320

 

2.01

 

 

 

69,780

 

 

348

 

2.02

 

Total Securities

 

783,768

 

 

6,783

 

3.51

 

 

 

774,962

 

 

6,797

 

3.48

 

 

 

639,580

 

 

4,657

 

2.95

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Federal Funds Sold

 

16,994

 

 

220

 

5.25

 

 

 

115,298

 

 

1,179

 

4.06

 

 

 

23,754

 

 

261

 

4.46

 

Loans, Net of Unearned Income

 

5,083,240

 

 

76,798

 

6.13

 

 

 

4,844,308

 

 

76,916

 

6.30

 

 

 

4,459,679

 

 

66,537

 

6.05

 

Restricted Investment in Bank Stocks

 

10,864

 

 

15

 

0.56

 

 

 

6,775

 

 

113

 

6.62

 

 

 

7,101

 

 

151

 

8.62

 

Total Earning Assets

 

5,914,513

 

 

83,926

 

5.75

 

 

 

5,762,933

 

 

85,140

 

5.86

 

 

 

5,150,908

 

 

71,744

 

5.65

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and Due from Banks

 

55,545

 

 

 

 

 

 

45,031

 

 

 

 

 

 

39,916

 

 

 

 

Other Assets

 

422,953

 

 

 

 

 

 

394,346

 

 

 

 

 

 

300,939

 

 

 

 

Total Assets

$

6,393,011

 

 

 

 

 

$

6,202,310

 

 

 

 

 

$

5,491,763

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES & SHAREHOLDERS’ EQUITY:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest-bearing Demand

$

1,382,567

 

$

5,417

 

1.59

%

 

$

1,269,387

 

$

5,546

 

1.73

%

 

$

1,051,325

 

$

4,681

 

1.81

%

Money Market

 

1,216,581

 

 

7,470

 

2.49

 

 

 

1,256,345

 

 

8,446

 

2.67

 

 

 

1,027,355

 

 

6,941

 

2.74

 

Savings

 

363,593

 

 

300

 

0.33

 

 

 

322,606

 

 

61

 

0.08

 

 

 

260,965

 

 

54

 

0.08

 

Time

 

1,579,915

 

 

14,661

 

3.76

 

 

 

1,597,442

 

 

15,877

 

3.94

 

 

 

1,589,083

 

 

16,588

 

4.23

 

Total Interest-bearing Deposits

 

4,542,656

 

 

27,848

 

2.49

 

 

 

4,445,780

 

 

29,930

 

2.67

 

 

 

3,928,728

 

 

28,264

 

2.92

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short term borrowings

 

71,111

 

 

702

 

4.00

 

 

 

226

 

 

5

 

8.78

 

 

 

24,892

 

 

290

 

4.72

 

Long-term debt

 

11,733

 

 

126

 

4.36

 

 

 

23,185

 

 

257

 

4.40

 

 

 

23,533

 

 

257

 

4.43

 

Subordinated debt and trust preferred securities

 

 

 

 

 

 

 

15,690

 

 

197

 

4.98

 

 

 

45,662

 

 

424

 

3.77

 

Total Interest-bearing Liabilities

 

4,625,500

 

 

28,676

 

2.51

 

 

 

4,484,881

 

 

30,389

 

2.69

 

 

 

4,022,815

 

 

29,235

 

2.95

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Noninterest-bearing Demand

 

850,936

 

 

 

 

 

 

844,818

 

 

 

 

 

 

752,980

 

 

 

 

Other Liabilities

 

71,022

 

 

 

 

 

 

69,518

 

 

 

 

 

 

55,004

 

 

 

 

Shareholders’ Equity

 

845,553

 

 

 

 

 

 

803,093

 

 

 

 

 

 

660,964

 

 

 

 

Total Liabilities & Shareholders’ Equity

$

6,393,011

 

 

 

 

 

$

6,202,310

 

 

 

 

 

$

5,491,763

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Interest Income

 

 

$

55,250

 

 

 

 

 

$

54,751

 

 

 

 

 

$

42,509

 

 

Taxable Equivalent Adjustment (1)

 

 

 

236

 

 

 

 

 

 

243

 

 

 

 

 

 

242

 

 

Net Interest Income (taxable equivalent basis)

 

 

$

55,486

 

 

 

 

 

$

54,994

 

 

 

 

 

$

42,751

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Yield on Earning Assets

 

 

 

 

5.75

%

 

 

 

 

 

5.86

%

 

 

 

 

 

5.65

%

Cost of funds

 

 

 

 

2.12

%

 

 

 

 

 

2.26

%

 

 

 

 

 

2.48

%

Rate on Supporting Liabilities

 

 

 

 

2.51

 

 

 

 

 

 

2.69

 

 

 

 

 

 

2.95

 

Average Interest Spread

 

 

 

 

3.24

 

 

 

 

 

 

3.17

 

 

 

 

 

 

2.70

 

Tax-Equivalent Net Interest Margin

 

 

 

 

3.80

 

 

 

 

 

 

3.79

 

 

 

 

 

 

3.37

(1)

Presented on a fully taxable-equivalent basis using a 21% federal tax rate and statutory interest expense disallowance.

(2)

Annualized ratios

ALLOWANCE FOR CREDIT LOSSES AND ASSET QUALITY (Unaudited):

(Dollars in thousands)

Mar. 31,

2026

 

Dec. 31,

2025

 

Sep. 30,

2025

 

Jun. 30,

2025

 

Mar. 31,

2025

Allowance for Credit Losses on Loans:

 

 

 

 

 

 

 

 

 

Beginning balance

$

36,091

 

 

$

37,337

 

 

$

37,615

 

 

$

35,838

 

 

$

35,514

 

 

 

 

 

 

 

 

 

 

 

Allowance for credit losses on loans acquired

 

4,415

 

 

 

 

 

 

 

 

 

343

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loans Charged off

 

 

 

 

 

 

 

 

 

Commercial real estate

 

 

 

 

 

 

 

 

 

CRE Nonowner Occupied

 

(499

)

 

 

(394

)

 

 

 

 

 

(691

)

 

 

 

CRE Owner Occupied

 

 

 

 

(346

)

 

 

 

 

 

 

 

 

 

Multifamily

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Farmland

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial and industrial

 

 

 

 

 

 

 

(91

)

 

 

(203

)

 

 

 

Construction

 

 

 

 

 

 

 

 

 

Residential Construction

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Construction

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Residential mortgage

 

 

 

 

 

 

 

 

 

1-4 Family 1st Lien

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1-4 Family Rental

 

(13

)

 

 

 

 

 

 

 

 

 

 

 

 

HELOC and Junior Liens

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consumer

 

(641

)

 

 

(28

)

 

 

(40

)

 

 

(15

)

 

 

(15

)

Total loans charged off

 

(1,153

)

 

 

(768

)

 

 

(131

)

 

 

(909

)

 

 

(15

)

Recoveries of loans previously charged off

 

 

 

 

 

 

 

 

 

Commercial real estate

 

 

 

 

 

 

 

 

 

CRE Nonowner Occupied

 

 

 

 

294

 

 

 

9

 

 

 

1

 

 

 

1

 

CRE Owner Occupied

 

93

 

 

 

 

 

 

 

 

 

 

 

 

 

Multifamily

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Farmland

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial and industrial

 

 

 

 

 

 

 

 

 

 

3

 

 

 

6

 

Construction

 

 

 

 

 

 

 

 

 

Residential Construction

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Construction

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Residential mortgage

 

 

 

 

 

 

 

 

 

1-4 Family 1st Lien

 

2

 

 

 

2

 

 

 

3

 

 

 

83

 

 

 

2

 

1-4 Family Rental

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HELOC and Junior Liens

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consumer

 

9

 

 

 

7

 

 

 

28

 

 

 

11

 

 

 

9

 

Total loans recovered

 

104

 

 

 

303

 

 

 

40

 

 

 

98

 

 

 

18

 

Balance before provision

 

39,457

 

 

 

36,872

 

 

 

37,524

 

 

 

35,370

 

 

 

35,517

 

Provision/(benefit) for credit losses – loans (1)

 

1,648

 

 

 

(781

)

 

 

(187

)

 

 

2,245

 

 

 

321

 

Balance, end of quarter

$

41,105

 

 

$

36,091

 

 

$

37,337

 

 

$

37,615

 

 

$

35,838

 

Nonperforming Assets

 

 

 

 

 

 

 

 

 

Total nonaccrual loans

$

29,641

 

 

$

22,951

 

 

$

17,957

 

 

$

18,216

 

 

$

24,045

 

 

 

 

 

 

 

 

 

 

 

Foreclosed real estate

 

8,420

 

 

 

7,806

 

 

 

9,346

 

 

 

9,816

 

 

 

1,402

 

Total nonperforming assets

 

38,061

 

 

 

30,757

 

 

 

27,303

 

 

 

28,032

 

 

 

25,447

 

 

 

 

 

 

 

 

 

 

 

Accruing loans 90 days or more past due

 

 

 

 

 

 

 

160

 

 

 

 

 

 

3

 

Total risk elements

$

38,061

 

 

$

30,757

 

 

$

27,463

 

 

$

28,032

 

 

$

25,450

 

(1)

Includes $2.3 million related to non-PCD loans acquired in the William Penn acquisition on April 30, 2025. This amount reflects accounting guidance in effect prior to the Company’s adoption of ASU 2025-08, under which the allowance for certain purchased loans was recognized through provision expense.

RECONCILIATION OF NON-GAAP MEASURES (Unaudited)

Explanatory note: This press release contains financial information determined by methods other than in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Mid Penn’s management uses these non-GAAP financial measures in their analysis of Mid Penn’s performance. For tangible book value, the most directly comparable financial measure calculated in accordance with GAAP is book value. We believe that this measure is important to many investors in the marketplace who are interested in changes from period to period in book value per common share exclusive of changes in intangible assets. Goodwill and other intangible assets have the effect of increasing total book value while not increasing tangible book value. Income tax effects of non-GAAP adjustments are calculated using the applicable statutory tax rate for the jurisdictions in which the charges (benefits) are incurred, while taking into consideration any valuation allowances or non-deductible portions of the non-GAAP adjustments. Adjusted earnings per common share excludes from income available to common shareholders certain expenses related to significant non-core activities, including merger-related expenses, net of income taxes. For return on average tangible common equity, the most directly comparable financial measure calculated in accordance with GAAP is return on average equity. The core efficiency ratio is often used by management to measure its noninterest expense as a percentage of its revenue. This non-GAAP disclosure has limitations as an analytical tool, should not be viewed as a substitute for financial measures determined in accordance with GAAP, and should not be considered in isolation or as a substitute for analysis of Mid Penn’s results and financial condition as reported under GAAP, nor is it necessarily comparable to non-GAAP performance measures that may be presented by other companies. Management believes that this non-GAAP supplemental information will be helpful in understanding Mid Penn’s ongoing operating results. This supplemental presentation should not be construed as an inference that Mid Penn’s future results will be unaffected by similar adjustments to be determined in accordance with GAAP. The reconciliation of the non-GAAP to comparable GAAP financial measures can be found in the tables below.

Tangible Book Value Per Common Share

(Dollars in thousands, except per share data)

Mar. 31,

2026

 

Dec. 31,

2025

 

Sep. 30,

2025

 

Jun. 30,

2025

 

Mar. 31,

2025

 

 

 

 

 

 

 

 

 

 

Shareholders’ Equity

$

887,405

 

$

814,058

 

$

796,323

 

$

775,708

 

$

667,933

Less: Goodwill

 

157,121

 

 

136,620

 

 

136,620

 

 

135,473

 

 

128,160

Less: Core Deposit and Other Intangibles

 

33,013

 

 

14,657

 

 

15,586

 

 

16,531

 

 

5,814

Tangible Equity

$

697,271

 

$

662,781

 

$

644,117

 

$

623,704

 

$

533,959

 

 

 

 

 

 

 

 

 

 

Common Shares Outstanding

 

25,296,763

 

 

23,047,203

 

 

23,039,223

 

 

22,915,194

 

 

19,362,094

 

 

 

 

 

 

 

 

 

 

Tangible Book Value per Share

$

27.56

 

$

28.76

 

$

27.96

 

$

27.22

 

$

27.58

Adjusted Earnings Per Common Share Excluding Non-Recurring Income and Expenses

 

Three Months Ended

(Dollars in thousands, except per share data)

Mar. 31,

2026

 

Dec. 31,

2025

 

Sep. 30,

2025

 

Jun. 30,

2025

 

Mar. 31,

2025

 

 

 

 

 

 

 

 

 

 

Net Income Available to Common Shareholders

$

8,706

 

$

19,447

 

 

$

18,297

 

$

4,762

 

$

13,742

Less: BOLI Death Benefit Income

 

331

 

 

223

 

 

 

71

 

 

1

 

 

83

Less: Recoveries on loans previously acquired in business combinations (1)

 

 

 

 

 

 

534

 

 

 

 

Less: Swap cancellation gain

 

 

 

83

 

 

 

279

 

 

 

 

Less: Gain on the closing of an investment of a reinsurance entity acquired from another institution

 

 

 

 

 

 

420

 

 

 

 

Less: Gain on sale of pension assets

 

 

 

192

 

 

 

 

 

 

 

Plus: Merger and Acquisition Expenses (2)

 

7,723

 

 

(39

)

 

 

233

 

 

11,011

 

 

314

Plus: Compensation expense for accelerated vesting of stock options and restricted stock awards

 

370

 

 

314

 

 

 

753

 

 

2,043

 

 

Plus: Legal settlement expense

 

665

 

 

 

 

 

 

 

 

 

Less: Tax Effect of Non-Recurring Expenses

 

1,839

 

 

 

 

 

207

 

 

2,741

 

 

66

Net Income Excluding Non-Recurring Income and Expenses

$

15,294

 

$

19,224

 

 

$

17,772

 

$

15,074

 

$

13,907

 

 

 

 

 

 

 

 

 

 

Weighted-average Shares Outstanding

 

23,949,008

 

 

23,045,983

 

 

 

23,005,504

 

 

21,566,617

 

 

19,355,867

 

 

 

 

 

 

 

 

 

 

Adjusted Earnings Per Common Share Excluding Non-Recurring Income and Expenses

$

0.64

 

$

0.83

 

 

$

0.77

 

$

0.70

 

$

0.72

(1)

These recoveries are recognized in noninterest income rather than a reduction to the allowance for credit losses, consistent with purchase accounting treatment, as expected credit losses on acquired loans were reflected in fair value adjustments at the acquisition date.

(2)

Includes release of merger and acquisition accruals related to William Penn acquisition in Q4 2025.

Return on Average Tangible Common Equity

 

Three Months Ended

(Dollars in thousands)

Mar. 31,

2026

 

Dec. 31,

2025

 

Sep. 30,

2025

 

Jun. 30,

2025

 

Mar. 31,

2025

 

 

 

 

 

 

 

 

 

 

Net income available to common shareholders

$

8,706

 

 

$

19,447

 

 

$

18,297

 

 

$

4,762

 

 

$

13,742

 

Plus: Intangible amortization, net of tax

 

1,027

 

 

 

735

 

 

 

746

 

 

 

588

 

 

 

338

 

 

 

9,733

 

 

 

20,182

 

 

 

19,043

 

 

 

5,350

 

 

 

14,080

 

 

 

 

 

 

 

 

 

 

 

Average shareholders’ equity

 

845,553

 

 

 

803,093

 

 

 

783,547

 

 

 

670,491

 

 

 

660,964

 

Less: Average goodwill

 

147,021

 

 

 

136,620

 

 

 

135,486

 

 

 

130,824

 

 

 

128,160

 

Less: Average core deposit and other intangibles

 

20,835

 

 

 

14,969

 

 

 

16,003

 

 

 

9,824

 

 

 

6,023

 

Average tangible common shareholders’ equity

$

677,697

 

 

$

651,504

 

 

$

632,058

 

 

$

529,843

 

 

$

526,781

 

 

 

 

 

 

 

 

 

 

 

Return on average tangible common equity(1)

 

5.82

%

 

 

12.29

%

 

 

11.95

%

 

 

4.05

%

 

 

10.84

%

(1)

Annualized ratio

Core Efficiency Ratio (Non-GAAP)

 

Three Months Ended

(Dollars in thousands)

Mar. 31,

2026

 

Dec. 31,

2025

 

Sep. 30,

2025

 

Jun. 30,

2025

 

Mar. 31,

2025

 

 

 

 

 

 

 

 

 

 

Noninterest expense

$

51,959

 

 

$

35,848

 

 

$

37,982

 

 

$

47,798

 

 

$

30,642

 

Less: Merger and acquisition expenses (1)

 

7,723

 

 

 

(39

)

 

 

233

 

 

 

11,011

 

 

 

314

 

Less: Compensation expense for accelerated vesting of stock options and restricted stock awards

 

370

 

 

 

314

 

 

 

753

 

 

 

2,043

 

 

 

 

Less: Intangible amortization

 

1,300

 

 

 

930

 

 

 

944

 

 

 

744

 

 

 

428

 

Less: Loss/(gain) on sale or write-down of foreclosed assets, net

 

491

 

 

 

203

 

 

 

471

 

 

 

 

 

 

(28

)

Less: Other expenses on foreclosed assets

 

427

 

 

 

445

 

 

 

 

 

 

 

 

 

 

Less: Legal settlement expense

 

665

 

 

 

 

 

 

 

 

 

 

 

 

 

Efficiency ratio numerator

 

40,983

 

 

 

33,995

 

 

 

35,581

 

 

 

34,000

 

 

 

29,928

 

 

 

 

 

 

 

 

 

 

 

Net interest income

 

55,250

 

 

 

54,751

 

 

 

53,629

 

 

 

48,206

 

 

 

42,509

 

Noninterest income

 

9,604

 

 

 

7,277

 

 

 

8,183

 

 

 

6,143

 

 

 

5,239

 

Less: BOLI Death Benefit

 

331

 

 

 

223

 

 

 

71

 

 

 

1

 

 

 

83

 

Less: Recoveries on loans previously acquired in business combinations (2)

 

 

 

 

 

 

 

534

 

 

 

 

 

 

 

Less: Swap cancellation gain

 

 

 

 

83

 

 

 

279

 

 

 

 

 

 

 

Less: Gain on the closing of an investment of a reinsurance entity acquired from another institution

 

 

 

 

 

 

 

420

 

 

 

 

 

 

 

Less: Gain on sale of pension assets

 

 

 

 

192

 

 

 

 

 

 

 

 

 

 

Less: Net gain on sales of investment securities

 

 

 

 

10

 

 

 

 

 

 

 

 

 

 

Efficiency ratio denominator

$

64,523

 

 

$

61,520

 

 

$

60,508

 

 

$

54,348

 

 

$

47,665

 

 

 

 

 

 

 

 

 

 

 

Core efficiency ratio

 

63.52

%

 

 

55.26

%

 

 

58.80

%

 

 

62.56

%

 

 

62.79

%

 

 

 

 

 

 

 

 

 

 

Tax effect on non-GAAP adjustments (3)

 

236

 

 

 

243

 

 

 

245

 

 

 

245

 

 

 

242

 

Tax-effected core efficiency ratio

 

63.29

%

 

 

55.04

%

 

 

58.57

%

 

 

62.28

%

 

 

62.47

%

(1)

Includes release of merger and acquisition accruals related to William Penn acquisition in Q4 2025.

(2)

These recoveries are recognized in noninterest income rather than a reduction to the allowance for credit losses, consistent with purchase accounting treatment, as expected credit losses on acquired loans were reflected in fair value adjustments at the acquisition date.

(3)

Tax effected using a 21% statutory federal tax rate.

 

Mid Penn Bancorp, Inc.

1-866-642-7736

Rory G. Ritrievi

Chair, President & Chief Executive Officer

Justin T. Webb

Chief Financial Officer

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo
Logo

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS

Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for patients and caregivers

Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET

EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive primary analysis results from its registrational trial, KYSA-8, of miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome (SPS). The data will be presented today in a late-breaking oral presentation at the American Academy of Neurology (AAN) Annual Meeting in Chicago.

In KYSA-8, a single dose of miv-cel delivered rapid, statistically significant and clinically meaningful improvements across all primary and secondary endpoints at 16 weeks, with the majority of patients regaining function, and all patients discontinuing chronic immunotherapies – outcomes not previously observed in SPS. Further, miv-cel was well-tolerated.

“The results from our KYSA-8 registrational trial mark a defining moment for Kyverna, and more importantly, for patients living with stiff person syndrome,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “We see compelling evidence that a one-time therapy can reset the immune system, reverse the course of disease, and free patients from lifelong treatment burden. With no approved therapies, we believe miv-cel could redefine the treatment paradigm for this debilitating, progressive disease. We are preparing our BLA submission for this initial indication, and the data strengthen our confidence in miv-cel’s therapeutic potential in myasthenia gravis, as well as other neurologic autoimmune diseases.”

KYSA-8 Clinical Trial Summary and Highlights from Primary Analysis

KYSA-8 is a single-arm registrational Phase 2 trial evaluating miv-cel in patients with SPS. The primary endpoints are the change from baseline in the Timed 25-Foot Walk (T25FW) at 16 weeks and the incidence and severity of adverse events (AEs). Secondary endpoints measuring disability, stiffness, hypersensitivity, and mobility include the Modified Rankin Scale (mRS), Distribution-of-stiffness Index (DSI), Heightened Sensitivity Scale (HSS), and Hauser Ambulation Index (HAI), respectively. Both DSI and HSS are SPS-specific clinical outcome measures designed to assess the extent of muscle stiffness and sensitivity to triggers of muscle spasms, respectively.

A total of 26 patients who had an inadequate response to off-label immunomodulatory treatment options received a single dose of 1×108 miv-cel CAR T cells. The data cut-off for the primary analysis was November 26, 2025, with a median follow-up of 6.5 months after miv-cel infusion (range, 4.4-12.2 months).

“The majority of patients with SPS suffer from a progressive condition that often results in loss of independence, reduced quality of life, and a high-risk of permanent disability,” said Amanda Piquet, M.D., FAAN, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine, Céline Dion Foundation Endowed Chair, and lead investigator of the KYSA-8 trial. “For decades, patients with SPS have had no approved therapies capable of altering the course of their disease. The ability of miv-cel to significantly decrease disability, stiffness, and hypersensitivity, and improve mobility – the key drivers of SPS morbidity – is unprecedented and highly promising for this underserved patient population.”

Efficacy highlights from the primary analysis following a single dose of miv-cel are as follows:

  • The trial met its primary endpoint, demonstrating a statistically significant improvement in the T25FW at Week 16 (p=0.0003), with a median improvement of 46% from baseline, regardless of baseline patient- and disease-related characteristics:
    • 81% of patients achieved clinically meaningful improvement (≥20% reduction from baseline), with nearly 1/3 of all patients walking at the speed of healthy adults by Week 16.
    • Of the 12 patients requiring a walking aid at baseline, 67% no longer needed walking assistance at Week 16, reflecting meaningful functional independence.
    • All 26 patients remained free of chronic immunotherapies at Week 16 and through last follow-up.
  • The trial met all secondary endpoints with significant (p<0.0001) mean improvements in mRS, HAI, DSI, and HSS of -0.8 (SD, 0.86), -1.6 (1.13), -1.5 (1.75), and -3.2 (2.01) points, respectively. 

Exploratory endpoints including additional efficacy measures, further supported the differentiated clinical profile of miv-cel:

  • Sustained clinical benefit associated with deep, transient B-cell depletion and broad immune reset.
  • Significant reductions in GAD65-autoantibody titers associated with SPS, consistent with clinical results and miv-cel’s mechanism of action.
  • Improvements in physical and mental functioning, including a more than 4-fold improvement over the minimal clinically important change in the 6-Minute Walk Test (6-MWT), and normalization toward healthy population benchmarks across the 36-Item Short Form Health Survey (SF-36) domains.

Miv-cel demonstrated a well-tolerated safety profile consistent with its potential for outpatient administration:

  • No high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.
  • Grade 3/4 neutropenia, a known AE associated with lymphodepletion and CAR T-cell therapy, was observed in four patients and was manageable.
  • Serious treatment-related AEs occurred in three patients, all of which resolved fully without sequalae.

“For neurologic autoimmune diseases such as stiff person syndrome, miv-cel is designed to achieve deep B-cell depletion, with the potential to impact immune activity within the central nervous system to enable a broad immune reset,” said Naji Gehchan, M.D., Chief Medical and Development Officer of Kyverna Therapeutics. “The findings from our primary analysis of miv-cel highlight its differentiated therapeutic profile, with the potential to deliver durable disease-free remission with just a single dose, without need for any immunotherapies for SPS. We believe the consistency of results across all primary, secondary and exploratory endpoints provide clinical evidence that miv-cel has the potential to transform patient care in SPS.”

Natural History Study Results Reinforce Significant Unmet Need in Patients with SPS

Outcomes from a large, multicenter, retrospective natural history study examining the impact of SPS on walking speed, were also presented at AAN.

The study included 153 patients treated with off-label immunomodulators or symptomatic medications and with longitudinal T25FW assessments available. The majority of patients showed minimal (<20%) or no improvement in T25FW and required increasing reliance on walking aids over time. Changes in T25FW correlated with changes in disability assessed by mRS over time.

This analysis supports the use of T25FW as a valid longitudinal measure of mobility and confirms its association with disability in patients with SPS. These findings further highlight the limited impact of current treatment approaches and reinforce the potential for miv-cel to change the treatment paradigm in SPS.

Investor Conference Call Details 

Kyverna will host a conference call tomorrow, April 22, at 7:00 a.m. ET to review these results, as well as updated Phase 2 generalized myasthenia gravis (gMG) data from the KYSA-6 trial, which were also presented at AAN. The conference call and live webcast details and presentation materials will be available on the “Events & Presentations” section of Kyverna’s Investor Relations webpage at ir.kyvernatx.com. An archived replay will also be available. 

Dial-In Registration Link: 
Conference Call Registration

Webcast Link: 
Kyverna AAN Conference Call

About KYSA-8 Trial Design

The registrational Phase 2 KYSA-8 trial is an open-label, single-arm, multicenter study evaluating the safety and efficacy of miv-cel in patients with SPS. A total of 26 adult patients with SPS were dosed in the trial. Key inclusion criteria included a confirmed SPS diagnosis, stiffness index ≥2, and inadequate response to prior immunomodulatory therapies.

Patients received lymphodepletion with low-dose cyclophosphamide and fludarabine followed by a single infusion of miv-cel at a target dose of 1×108 CAR T cells. The primary endpoints were the change from baseline in the T25FW at Week 16 and safety. Secondary endpoints included the change from baseline in mRS, DSI, HAI, and HSS. Patients will be followed for one year.

Primary Endpoints
Timed 25-Foot Walk (T25FW) Validated tool capturing improvement in walking ability
Safety Incidence and severity of AEs
Secondary Endpoints
Modified Rankin Score (mRS) Change in degree of disability
Hauser Ambulation Index (HAI) Change in time and degree of assistance to complete timed 25-foot walk
Distribution of Stiffness Index (DSI) Change in muscle stiffness across body regions
Heightened Sensitivity Scale (HSS) Change in muscle spasms


About Stiff Person Syndrome (SPS)

SPS is a rare, progressive neurologic autoimmune disease characterized by muscle stiffness and painful muscle spasms, impacting mobility and gait. Stiffness, rigidity, and spasms in the torso, arms, and legs lead to progressive disability causing up to 80% of patients to lose mobility, requiring walking aid assistance or wheelchair use1-3. SPS has been shown to lead to permanent disability and increased risk of mortality3. Most patients with SPS have antibodies to glutamic acid decarboxylase 65 (GAD65) or the glycine receptor, which disrupt normal inhibitory neurotransmission, contributing to the hallmark symptoms of SPS. There are currently no FDA-approved treatments for SPS. Current treatment options include symptomatic treatments, off-label immunotherapies, such as intravenous immunoglobulin (IVIg), rituximab and plasmapheresis, as well as supportive care and physical, speech, occupational, and psychiatric therapy; however, the majority of patients have inadequate or no response to these treatment options. An estimated 6,000 patients are diagnosed with SPS in the United States4-5.

About miv-cel (mivocabtagene autoleucel, KYV-101)

Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability, which is under investigation for B-cell-driven autoimmune diseases. With a single administration, miv-cel has potential to achieve deep B-cell depletion and immune system reset to deliver durable drug-free, disease-free remission in autoimmune diseases. 

About Kyverna Therapeutics

Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. The Company’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its initial indications in stiff person syndrome and generalized myasthenia gravis. The Company is also advancing additional clinical and investigator-sponsored studies, including in multiple sclerosis and rheumatoid arthritis, to inform future priority indications and develop next-generation CAR T platforms to improve access and patient experience. For more information, please visit https://kyvernatx.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: miv-cel’s potential in SPS, including the ability of miv-cel to demonstrate statistically significant, durable clinical benefit, to achieve robust and durable improvements in mobility, to reduce or reverse disability scores, stiffness or hypersensitivity, and to eliminate the need for chronic immunotherapies; the potential for miv-cel to impact immune activity within the central nervous system to enable a broad immune reset, to deliver durable disease-free remission with just a single dose without need for any immunotherapies for SPS, to become the first and only approved treatment for SPS, to transform care or fundamentally change the treatment paradigm for SPS patients and caregivers or for other B-cell-driven autoimmune diseases and to strengthen confidence in miv-cel’s therapeutic potential in myasthenia gravis and other neurologic autoimmune diseases; miv-cel’s potential outpatient administration; Kyverna’s BLA submission; the potential impact of the results from the KYSA-8 registrational trial on Kyverna and SPS patients; Kyverna’s advancement of its potentially first-in-class neuroimmunology franchise with its initial indications in SPS and gMG and of additional clinical and investigator-sponsored studies, and the potential for such advancement to improve access and patient experience; and the anticipated timing for Kyverna’s conference call and webcast and presentations at the AAN Annual Meeting and the topics expected to be discussed during such conference call and webcast and presentations. . Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; the possibility that the FDA or other regulatory agencies may require additional trials or studies to support its intended BLA submission; intellectual property rights; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts: 
Investors: [email protected] 
Media: [email protected]

____________________
1 Rakocevic G, et al. BMC Neurol. 2019;19:1.
2 Dalakas MC. Nat Rev Neurol. 2024;20(10):587-601.
3 Duddy ME, Baker MR. Front Neurol Neurosci. 2009;26:147-165.
4 Crane PD, et al. Neurology. 2024;103(12):e210078.
5 Analysis of 2024 Komodo U.S. Claims Data.



Enerflex Ltd. Announces Timing of First Quarter Financial and Operational Results and Schedules Virtual Investor Update

CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) plans to release its financial results and operating highlights for the three months ended March 31, 2026, on Thursday, May 7, 2026 prior to market open. Results will be communicated by news release and will be available on the Company’s website at www.enerflex.com and under the electronic profile of the Company on SEDAR+ and EDGAR at www.sedarplus.ca and www.sec.gov/edgar, respectively.

Investors, analysts, members of the media, and other interested parties, are invited to participate in a conference call and audio webcast on Thursday, May 7, 2026 at 8:00 a.m. (MT), where members of senior management will discuss the Company’s results. A question-and-answer period will follow.

To participate, register at https://register-conf.media-server.com/register/BI6515d65feedd4a68be887d88f452621e. Once registered, participants will receive the dial-in numbers and a unique PIN to enter the call. The audio webcast of the conference call will be available on the Enerflex website at www.enerflex.com under the Investors section or can be accessed directly at https://edge.media-server.com/mmc/p/jpr3iwfx.


Virtual Investor Update

Enerflex will host a virtual Investor Update on Wednesday, May 27, 2026 at 8:00 am MT (10:00am ET). Enerflex’s President and CEO, Paul Mahoney, will highlight the Company’s outlook and strategic priorities with a question and answer period to follow.

Registration for the Virtual Investor Update can be made using the following https://edge.media-server.com/mmc/p/eyz29mbq. Participants can join by webcast to follow along with the presentation. The presentation will be made available on Enerflex’s website prior to the start. Questions can be submitted via the webcast or asked on the dial-in:

Dial-in numbers: https://register-conf.media-server.com/register/BI8e02cded3fae4a3dbb8d89234ae4be38.

Shortly after the live webcast, an archived version will be available on Enerflex’s website.

ADVISORY REGARDING FORWARD-LOOKING INFORMATION
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” (and together with “forward-looking information”, “FLI”) within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are FLI. In particular, this news release includes (without limitation) FLI pertaining to the Company’s expectation to release its financial results and operating highlights for the three months ended March 31, 2026, on Thursday, May 7, 2026 prior to market open; and the Company’s intention to host a virtual Investor Update on Wednesday, May 27, 2026, and the expected content of such update.

The FLI included in this news release is made as of the date of this news release and is based on the information available to the Company at such time and, other than as required by law, Enerflex disclaims any intention or obligation to update or revise any FLI, whether as a result of new information, future events, or otherwise. This news release and its contents should not be construed, under any circumstances, as investment, tax, or legal advice.

ABOUT ENERFLEX
Enerflex is a leading provider of modular natural gas, power, and treated water technology solutions, delivering value through disciplined execution and a deliberate approach to where we compete. Our customer focused delivery model supports operational excellence, innovation, and scalability across our global footprint with a focus on creating long-term shareholder value.

With approximately 4,400 engineers, manufacturers, technicians, professionals, and innovators, Enerflex is bound together by a shared vision: Transforming Energy for a Sustainable Future. The Company remains committed to the future of natural gas and the critical role it plays, while focused on sustainability offerings to support the world’s energy needs.

Enerflex’s common shares trade on the Toronto Stock Exchange under the symbol “EFX” and on the New York Stock Exchange under the symbol “EFXT”. For more information about Enerflex, visit www.enerflex.com.

For investor and media enquiries, contact:

Paul Mahoney
President and Chief Executive Officer
E-mail: [email protected]

Preet S. Dhindsa
Senior Vice President and Chief Financial Officer
E-mail: [email protected]

Jeff Fetterly
Vice President, Corporate Development and Capital Markets
E-mail: [email protected]



Navan 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Navan, Inc. – NAVN

Navan 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Navan, Inc. – NAVN

NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 24, 2026 to file lead plaintiff applications in a securities class action lawsuit against Navan, Inc. (“Navan” or the “Company”) (NasdaqGS: NAVN), if they purchased or otherwise acquired the Company’s shares pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the “Offering Documents”) issued in connection with Navan’s October 2025 initial public offering (the “IPO”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased shares of Navan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-navn/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by April 24, 2026.

About the Lawsuit

According to the Complaint, Navan and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that the Company had increased its “sales and marketing” expenses for the quarter ending October 31, 2025 to nearly $95 million, or by 39% compared to $68.5 million sales and marketing expenses in the quarter ending July 31, 2025. When the true details entered the market, the lawsuit claims that the Company’s shares fell sharply.

The case is McCown v. Navan, Inc., Case No. 26-cv-01550.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

KEYWORDS: Louisiana United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Leading Independent Proxy Advisory Firm Glass Lewis Supports Impactive’s Case for Change at WEX

Leading Independent Proxy Advisory Firm Glass Lewis Supports Impactive’s Case for Change at WEX

Glass Lewis Recommends Shareholders Vote FOR Impactive Nominees Kurt Adams and Lauren Taylor Wolfe and WITHHOLD Support on WEX Board Chair and CEO Melissa Smith and Compensation Committee Chair Stephen Smith

Concludes that Separation of CEO and Chair Role is in Shareholders’ Interests in Light of Sustained Underperformance Under Melissa Smith’s Tenure

Determines Impactive Has “Articulated a Coherent Set of Concerns Regarding Oversight and Capital Allocation”

Impactive Urges Shareholders to Vote on the WHITE Proxy Card to Elect All Three of Its Highly Qualified Nominees

NEW YORK–(BUSINESS WIRE)–
Impactive Capital, LP (“Impactive” or “we”), together with its affiliates, is one of the largest shareholders of WEX Inc. (NYSE: WEX) (the “Company” or “WEX”) with an ownership interest of approximately 4.9%. Impactive announced today that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended that shareholders vote on the WHITE proxy card FOR the election of Impactive director nominees Kurt Adams and Lauren Taylor Wolfe to the Company’s Board of Directors (the “Board”) and WITHHOLD on Board Chair and CEO Melissa Smith and director and Compensation Committee Chair Stephen Smith.

Impactive stated:

“We appreciate Glass Lewis’ recognition of the merits of our case for change and its recommendation that shareholders vote to elect Kurt Adams and Impactive principal and significant shareholder representative Lauren Taylor Wolfe to WEX’s Board. Glass Lewis’ report is unequivocal: WEX’s persistent underperformance, poor capital allocation, and insufficient Board oversight demand new voices in the boardroom — directors aligned with shareholders and accountable for results. Glass Lewis’ recommendation to separate the Chair and CEO roles by withholding support from Melissa Smith is particularly notable, highlighting the critical importance of reversing the Company’s prolonged underperformance and governance shortcomings. Electing all three of our highly qualified nominees is the most effective path to strengthening oversight, improving capital allocation, and positioning WEX to deliver sustainable shareholder value.”

In its report, Glass Lewis supported Impactive’s case for change, writing:1

  • “[Impactive] has articulated a credible case for enhanced oversight, and the performance record, while not uniformly negative, reflects a sustained period of relative underperformance against the most relevant comparators over long- and medium-term horizons that the Company has not fully rebutted through its operational narrative.”

  • “Given that [Impactive’s] campaign has demonstrated credibility, appears to have contributed to a more favorable market reassessment, and has articulated a coherent set of concerns regarding oversight and capital allocation, shareholders are justified in concluding that direct Impactive representation on the board is appropriate.”

Glass Lewis commented on the qualifications of Impactive’s nominees:

  • “[Lauren Taylor Wolfe’s] direct involvement in the campaign and investment thesis provides clear alignment with the perspectives advanced in support of change, as well as detailed familiarity with the Company’s strategy, performance, and perceived areas of improvement.”

  • “[Kurt Adams] brings relevant financial services, regulatory, and governance experience that appears additive to the board, and his independence from both the Company and [Impactive] should enable him to contribute constructively while reinforcing board accountability.”

In making its recommendation to withhold on Melissa Smith and Stephen Smith, Glass Lewis wrote the following:

  • “The combination of the chair and CEO roles, the level of shareholder dissent observed in 2025, and the Company’s sustained underperformance over [Melissa Smith’s] tenure as chair together support the conclusion that greater separation between executive leadership and board oversight is in shareholders’ interests.”

  • “In this context, it is relevant that [Impactive’s] proposal relates to Ms. Smith’s position as chair, rather than her executive role. Should she not be re-elected to the board, Ms. Smith would continue to serve as CEO.”

  • “… [Impactive] has articulated a range of governance and performance-related concerns … with respect to leadership accountability, compensation oversight, and board responsiveness. These concerns appear most directly attributable to Melissa Smith, given her combined executive and board leadership role.”

  • “As chair of the Compensation Committee, [Stephen Smith] bears direct responsibility for a compensation framework that the Dissident has credibly argued has not adequately reflected shareholder experience over the relevant period.”

Glass Lewis commented on WEX’s poor corporate governance underscored by low shareholder support at the 2025 AGM, stating:

  • “The level of shareholder dissent observed at the 2025 annual meeting, particularly with respect to the Company’s leadership, suggests that the Dissident’s concerns resonated with a meaningful portion of the shareholder base and that a degree of board-level accountability is warranted.”

  • “…Ms. Smith received more than 30% votes against her re-election in 2025, which constitutes a significant level of shareholder opposition. This outcome followed the Dissident’s 2025 campaign opposing her re-election, suggesting that the level of dissent may, at least in part, reflect shareholder alignment with the concerns advanced by the Dissident. Under prevailing market standards, dissent exceeding 20% is generally viewed as a meaningful signal of investor concern.”

For more information, including how to vote for Impactive’s three nominees using the WHITE proxy card, please visit www.WakeUpWEX.com.

If you have any questions, require assistance in voting your WHITE universal proxy card, or need additional copies of Impactive’s proxy materials, please contact:

 

Okapi Partners LLC

1212 Avenue of the Americas, 17th Floor

New York, New York 10036

Stockholders may call toll-free: (877) 285-5990

Banks and Brokers call: (212) 297-0720

E-mail: [email protected]

ADDITIONAL INFORMATION

Impactive Capital Master Fund LP, together with the other participants in its proxy solicitation (collectively, “Impactive”), has filed a definitive proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit proxies with respect to the election of Impactive’s slate of highly qualified director candidates and the other proposals to be presented at the 2026 annual meeting of stockholders (the “Annual Meeting”) of WEX Inc., a Delaware corporation (“WEX” or the “Company”). Stockholders are advised to read the proxy statement and any other documents related to the solicitation of stockholders of the Company in connection with the Annual Meeting because they contain important information, including information relating to the participants in Impactive’s proxy solicitation. These materials and other materials filed by Impactive with the SEC in connection with the solicitation of proxies are available at no charge on the SEC’s website at http://www.sec.gov. The definitive proxy statement and other relevant documents filed by Impactive with the SEC are also available, without charge, by directing a request to Impactive’s proxy solicitor, Okapi Partners LLC, at its toll-free number (877) 285-5990 or via email at [email protected].

____________________

1 Permission to quote Glass Lewis was neither sought nor received. Emphasis added.

Investor Contacts:

Bruce Goldfarb / Chuck Garske / Lisa Patel

Okapi Partners

(877) 285-5990

[email protected]

OR

[email protected]

Media Contact:

Longacre Square Partners

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Shoals Technologies Group, Inc. Announces Participation in Upcoming Events for the Investor Community

PORTLAND, Tenn., April 21, 2026 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a global leader in electrical infrastructure solutions for the energy transition market, announced today its participation in the following upcoming investor events:

May 7, 2026: JP Morgan Virtual Fireside Chat

Shoals’ CEO, Brandon Moss, and CFO, Dominic Bardos, will participate in a fireside chat with covering analyst Mark Strouse. Interested investors should contact their JP Morgan sales representative.

May 13, 2026: Johnson Rice Virtual Fireside Chat

Shoals’ VP of Finance & Investor Relations, Matt Tractenberg, and SVP of Sales, Karen Bazela, will participate in a fireside chat with covering analyst Marty Malloy. Interested investors should contact their Johnson Rice sales representative.

May 27, 2026: Bank of America Power, Utilities and Cleantech Conference in New York

Shoals’ CFO, Dominic Bardos, and Investor Relations Manager, Corbin Smith, will host in-person investor meetings. Interested investors should contact their Bank of America sales representative.

May 28, 2026: TD Cowen Technology, Media & Telecom Conference in New York

Shoals’ CFO, Dominic Bardos, SVP of Sales, Karen Bazela, and Investor Relations Manager, Corbin Smith, will host in-person investor meetings. Interested investors should contact their TD Cowen sales representative.

June 2, 2026: RBC Global Energy, Power & Infrastructure Conference in New York

Shoals’ VP of Finance & Investor Relations, Matt Tractenberg, and Senior Director of Business Development, Ed Lo Bianco, will host in-person investor meetings. Interested investors should contact their RBC sales representative.

June 17, 2026: Roth Conference in London

Shoals’ VP of Finance & Investor Relations, Matt Tractenberg, and VP of Marketing & External Communications, Lindsey Williams, will host in-person investor meetings. Interested investors should contact their Roth sales representative.

June 24, 2026: JP Morgan Natural Resources Conference in New York

Shoals’ CEO, Brandon Moss, and VP of Finance & Investor Relations, Matt Tractenberg, will host in-person investor meetings. Interested investors should contact their JP Morgan sales representative.

June 25, 2026: UBS Virtual Fireside Chat

Shoals’ CFO, Dominic Bardos, and VP of Finance & Investor Relations, Matt Tractenberg, will participate in a fireside chat with covering analyst Jon Windham. Interested investors should contact their UBS sales representative.

About Shoals Technologies Group, Inc.

Shoals Technologies Group is a leading manufacturer of advanced electrical infrastructure solutions for mission-critical applications across utility‑scale solar, battery storage, and data center power systems. Since its founding in 1996, the Company has designed innovative technologies and systems solutions that allow its customers to substantially increase installation efficiency and safety while improving system performance and reliability at scale. Shoals Technologies Group is a recognized leader in the energy transition industry. For additional information, please visit: https://www.shoals.com.

Contacts:

Investor Relations:

Matt Tractenberg, VP of Finance and Investor Relations
Email: [email protected]

Media:

Lindsey Williams, VP of Marketing and External Communications
Email: [email protected]